They are prescribed when a healthcare provider determines that a customized approach is appropriate based on a patients individual needs
Type 2 diabetes mellitus (DM2) affects a 13.8% of the Spanish population1 and its prevalence is expected to increase in the future.2 The presence of DM2 increases significantly the risk of cardiovascular events, chronic kidney disease (CKD), and premature death3,4 and as its prevalence increases it is expected to rise the incidence of microvascular and macrovascular complications.5 Until the last decade, the control of blood glucose, blood pressure, dyslipidemia, and the use of inhibitors of the renin-angiotensin system (iSRA) have been the only strategies available to reduce cardiovascular and renal risk in this population
It provides a cost-effective entry point while maintaining the appetite-suppression benefits of GLP-1 activation
Patients seeking GLP-1 therapy should consult their healthcare provider about FDA-approved injectable or oral formulations and proper administration techniques for those products
During your initial consultation, we review your metabolic panel, medical history, current medications, and goals
